Volume 80, Issue 6 pp. 863-867
Experimental Cancer

Increased resistance of GPx-1 transgenic mice to tumor promoter–induced loss of glutathione peroxidase activity in skin

Jean-François Bilodeau

Jean-François Bilodeau

Unité de Santé et Environnement, Centre de Recherche du CHUQ Pavillon CHUL and Département de Médecine, Université Laval, Québec, Canada

Search for more papers by this author
Marc-Edouard Mirault

Corresponding Author

Marc-Edouard Mirault

Unité de Santé et Environnement, Centre de Recherche du CHUQ Pavillon CHUL and Département de Médecine, Université Laval, Québec, Canada

CHUL, Laboratoire 9700, 2705 Boulevard Laurier, Sainte-Foy, PQ Canada G1V 4G2. Fax: (418) 654–2159.Search for more papers by this author

Abstract

Reactive oxygen species formation is strongly suspected to play a role in multistep carcinogenesis, notably in tumor promotion. The tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) induces peroxide production, oxidative damage to DNA and inflammation in mouse skin. TPA is also known to cause a decrease in the activity of several anti-oxidant enzymes including glutathione peroxidases (GPx). The observation that several anti-oxidants can inhibit TPA-mediated tumor promotion suggests that a decline in GPx activity could contribute to tumor promotion. We report here the effects of TPA on GPx activity in the skin of transgenic GPx mice that contain human GPx-1 transgenes under the regulation of a metallothionein IIA promoter. As expected, no significant difference in basal level of skin GPx activity was detected in the 3 lines of tg-MT-GPx mice investigated compared with non-transgenic controls. A single topical application of TPA induced gradually, over 20 hr, a small but detectable increase in GPx mRNA and protein levels in skin of non-transgenic mice and a contrasting decrease in both selenium-dependent and selenium-independent GPx activity. The extent of GPx induction was more pronounced in transgenic mice, and in contrast with non-transgenic mice, no significant loss of GPx activity was observed in the TPA-treated skin of these mice. Transgenic mice may, therefore, offer a novel model suitable to assess the role of GPx-1 in skin carcinogenesis, without the potential disadvantage of abnormally high levels of GPx activity produced constitutively in other transgenic models. Int. J. Cancer 80:863–867, 1999. © 1999 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.